PDF
File
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
"The Group grew organically by 4.3%, giving us a stable start to the year. Demand for Arjo's products and solutions was high, and despite a volatile market we remain confident that we will reach the target of 3-5% organic growth for the full-year," says Joacim Lindoff, President and CEO of Arjo.
January-March 2023 in brief- Net sales increased to SEK 2,638 M (2,370).
- Adjusted EBITDA amounted to SEK 474 M (490).
- Adjusted operating profit amounted to SEK 196 M (237).
- Profit after financial items amounted to SEK 126 M (218).
- Earnings per share amounted to SEK 0.35 (0.60).
- Cash flow from operations increased to SEK 271 M (25).
- Cash conversion increased to 59.2% (5.3).
Telephone conference
Fund managers, analysts and media are invited to participate in a conference call and presentation of the report on April 20 at 08.00 CEST via the following link: https://ir.financialhearings.com/arjo-q1-report-2023
Those who wish to ask questions verbally via the teleconference will need to register via the link below. A phone number and a conference ID will be provided after registration in order to access the conference. Link to registration:
https://conference.financialhearings.com/teleconference/?id=5005701
Alternatively, use the following link to download the presentation:
https://www.arjo.com/int/about-us/investors/reports--presentations/2023/
A recorded version of the conference is accessible for three years via the following link:
https://ir.financialhearings.com/arjo-q1-report-2023
For more information, please contact:
Maria Nilsson, Acting EVP Communications & Public Relations
Tel: +46 734 244 515
Email: maria.nilsson@arjo.com
Sara Ehinger, VP Investor Relations & Corporate Communications
Tel: +46 723 597 794
Email: sara.ehinger@arjo.com
This information is information that Arjo AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 07:00 CEST on April 20, 2023.
About Arjo
At Arjo, we believe that empowering movement within healthcare environments is essential to quality care. Our products and solutions are designed to promote a safe and dignified experience through patient handling, medical beds, personal hygiene, disinfection, diagnostics, and the prevention of pressure injuries and venous thromboembolism. With 6,800 people worldwide and 65 years caring for patients and healthcare professionals, we are committed to driving healthier outcomes for people facing mobility challenges. www.arjo.com